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Abstract 
 
Objective. To ascertain whether strategies of treatment with a biological disease-
modifying antirheumatic drug (bDMARD) were cost-effective in an English setting. 
Results are presented for those patients with moderate-to-severe rheumatoid 
arthritis (RA) and those with severe RA. 
 
Methods. An economic model to assess the cost-effectiveness of seven bDMARDs 
was developed. A systematic literature review and network meta-analysis was 
undertaken to establish relative clinical effectiveness. The results together with 
estimates of:  Health Assessment Questionnaire (HAQ) score following European 
League Against Rheumatism response; annual costs, and utility, per HAQ band; 
trajectory of HAQ for patients on bDMARDs; and trajectory of HAQ for patients on 
non-biologic therapy (NBT) were used to populate the model. Results were 
presented as those associated with the strategy with the median cost-effectiveness. 
Supplementary analyses were undertaken assessing the change in cost-
effectiveness where only patients with the most severe prognoses on NBT were 
provided with bDMARD treatment. The cost per QALY values were compared with 
reported thresholds from the National Institute for Health and Care Excellence of 
£20,000 to £30,000. 
 
Results. In the primary analyses, the cost per QALY of a bDMARD strategy was 
£41,600 for patients with severe RA and £51,100 for those with moderate-to-severe 
RA. Under the supplementary analyses the cost per QALY fell to £25,300 for those 
with severe RA and to £28,500 for those with moderate-to-severe RA. 
 
Conclusion. The cost-effectiveness of bDMARDs in RA in England is questionable 
and only meets current accepted levels in subsets of patients with the worst 
prognoses.  
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Short Running Title: 
Cost-effectiveness of bDMARDs.  
  
Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by 
progressive, irreversible, joint damage, impaired joint function, pain and tenderness 
caused by swelling of the synovial lining of joints and is manifested with increasing 
disability and reduced quality of life.(1) RA is associated with substantial costs both 
directly (drug acquisition and hospitalisation) and indirectly due to reduced 
productivity.(2) RA has long been reported as being associated with increased 
mortality,(3,4) particularly due to cardiovascular events.(5) A range of biological 
disease modifying anti-rheumatic interventions(bDMARDs) is available with proven 
efficacy compared with conventional disease modifying anti-rheumatic 
interventions(cDMARDs). However, these are expensive treatments, costing in the 
region of £9,000 per annum making decisions based on cost-effectiveness 
particularly important. In England, the National Institute for Health and Care 
Excellence (NICE) make recommendations on the use of new and existing 
medicines and treatments within the National Health Service. NICE guidance 
restricts the use of bDMARDs to patients who have failed at least two cDMARDs and 
who have a disease activity score in 28 joints (DAS28) > 5.1. For treatment to be 
continued patients need to demonstrate at least a moderate European League 
Against Rheumatism (EULAR) response by 6 months.  
 
NICE decided to review guidance on the use of bDMARDs to allow a comparison 
between interventions and to consider extending existing guidance to patients with 
less severe RA. This paper reports the economic model structure, parameter inputs 
and estimated cost-effectiveness of sequences of bDMARDs compared with no use 
of bDMARDs undertaken by the Assessment Group. This work formed part of the 
evidence base used by NICE to form the guidance for Technology Appraisal 375.(6) 
The economic model differs from previously published models by other researchers 
in that: it is based on EULAR response rather than American College of  
Rheumatology (ACR) responses that are not used in UK clinical practice;  it used 
non-linear,  Health Assessment Questionnaire (HAQ) score progression whilst on 
cDMARDs based on a comprehensive review and analysis of HAQ progression; it 
assesses the cost-effectiveness in moderate-to-severe, and severe RA patients 
independently; and it allows fully incremental analyses of treatment strategies using 
different first-line bDMARDs. This paper concentrates on the cost-effectiveness 
results for those patients who can tolerate methotrexate (MTX) with the results for 
strategies without MTX provided elsewhere.(7,8)  
 
Methods 
Economic model  
An economic model was developed to estimate the cost-effectiveness within 
England of sequences of bDMARDs. The model is used to synthesis evidence from 
a range of sources, including clinical trials, in order to estimate the costs and health 
benefits of different treaWPHQWVRYHUSDWLHQWV¶OLIHWLPHV7KHUDWLRRIDGGLWLRQDOFRVWWR
additional health benefits, measured in quality adjusted life years (QALYs), is the 
incremental cost effectiveness ratio (ICER). The ICER is compared with a published 
threshold (£20,000 - £30,000 per QALY in this instance for NICE) to help determine 
if new treatments will add more to population health than will be lost from the 
withdrawal of other NHS services. The conceptual model is depicted in Figure 1 and 
took an NHS and Personal Social services perspective. The model used an 
individual patient, time to event approach using a lifetime time horizon with both 
costs and benefits discounted at 3.5% per annum in accordance with NICE 
recommendations.(9) Individual patients were sampled with characteristics 
resembling those in the British Society for Rheumatology Biologics Register 
(BSRBR). An outline of the methods is provided here: see Stevenson et al.(7) for full 
technical details.  
 
 
The population evaluated. 
Analyses were conducted separately for patients with moderate-to-severe RA 
GHILQHGDV WKRVHZLWKD'$6VFRUH!DQG and for patients with severe 
RA (defined as those with a DAS28 > 5.1). Patients with prior experience of MTX 
were sampled using patient characteristics from the BSRBR for those receiving their 
first bDMARD which allowed correlation to be maintained between the following 
characteristics: age; sex; disease duration; DAS28; previous DMARDs; HAQ score; 
and weight. Details of the midpoint values and distributions are provided 
elsewhere.(7)  
 
The strategies evaluated within the economic model 
The focus of the NICE appraisal was on the cost-effectiveness of the initial bDMARD 
which was one of: adalimumab (ADA); etanercept (ETN); infliximab (IFX); 
certolizumab pegol (CTZ); golimumab (GOL); tocilizumab (TCZ) and abatacept 
(ABT). ABT was available in both subcutaneous (SC) and intravenous (IV) 
formulations. The remaining treatments after all first line bDMARDs were assumed to 
follow NICE guidance and were rituximab (RTX) + MTX, then TCZ + MTX, if TCZ + 
MTX was not used first-line, followed by a range of non-biologic therapies (NBT) 
which was a term defined to encompass a selection of non-biological treatments that 
clinicians may feel is appropriate for individual patients, typically MTX, and 
sulphasalazine.(10) All seven bDMARD strategies were compared against each 
other, and with a strategy of cDMARD (MTX) followed by NBT. It was assumed that 
in accordance with NICE guidance patients would have received at least two 
cDMARDs before considering the use of a bDMARD.(11) 
 
The efficacy of bDMARDs, cDMARDs and NBT. 
Literature searching was performed with a cut-off date of July 2013, as the 
Assessment Group report was submitted to NICE in August 2013. For inclusion in 
the network meta-analysis (NMA) a study needed to present information on ACR 
and/or EULAR response between 22 and 30 weeks inclusive and needed to recruit 
patients with moderate-to-severe RA or severe RA.  These studies were deemed 
generalizable to the patients modelled. 
This paper provides the results for studies conducted in patients without previous 
bDMARD experience: results including studies with a small proportion of bDMARD 
experienced people are provided elsewhere.(7) A NMA, implemented within a 
Bayesian framework, was undertaken to synthesise both direct and indirect evidence 
on relative EULAR responses produced by each intervention and assuming that 
cDMARDs could be grouped together. The analyses conducted for those with 
moderate-to-severe or severe RA was based on 16 randomised controlled 
trials.(12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29) Point estimates from 
the NMA for the interventions within the decision problem are shown in Figure 2. As 
expected, bDMARDs are more efficacious than NBT. No EULAR data was available 
for ABT SC. Based on work undertaken by Malottki et al.(30) the efficacy of 
RTX+MTX was set equal to that for ABA IV + MTX. It was assumed that NBT 
provided no EULAR response. 
 
The change in HAQ related to EULAR response 
The change in HAQ score conditional on EULAR response was calculated using 
data (2417 Good EULAR responses and 5492 moderate EULAR responses) from 
the BSRBR. The average reductions in HAQ score were estimated to be 0.317 
(standard error 0.048) for moderate responders and 0.672 for good responders 
(standard error 0.112). 
 
The trajectory of HAQ while on bDMARDs or NBT 
Three-year data from the BSRBR showed no evidence to challenge previous 
assumptions of no HAQ progression whilst a patient was on a bDMARD. For those 
patients on NBT, we used estimates from previous work by Norton et al.(31) which 
identified four distinct trajectories of HAQ in the Early Rheumatoid Arthritis Study 
(ERAS) and which showed that the rate of HAQ worsening decreases over time. 
These analyses were re-run incorporating covariates for patient characteristics (age; 
sex; disease duration; DAS28 score; and number of previous cDMARDs) with the 
results shown in Figure 3. For each individual patient the probabilities of belonging to 
each trajectory was calculated with the predicted HAQ progression being the 
weighted average of the four trajectories.  
Alternative analyses were also undertaken to evaluate the ICERs if faster rates of 
HAQ progression were used. These analyses are described in detail in Gibson et 
al.(32), which extended approach of Norton et al to assess the potential impact of 
patient dropout from the ERAS dataset on the four trajectories. We used the 
estimates that had the greatest rate of HAQ worsening over fifteen years to illustrate 
a lower limit of the ICER. The HAQ trajectories for the Gibson et al. analysis are 
shown in Figure 4. There was a delay between the Assessment Group being 
submitted to NICE and the final appraisal decision because the NICE appraisal 
process was suspended until these additional analyses were completed. In both the 
base case and supplementary analyses, it was assumed that that there was no 
further progression beyond 15 years, although a scenario which allowed the rate of 
progression seen between years 12 and 15 in trajectories three and four to be 
continued until 40 years was evaluated. Whilst the data to inform HAQ progression 
were relatively dated and do not reflect current first line cDMARD treatment these 
were believed appropriate to represent NBT in a population who had received at 
least 2 prior cDMARDs, and in the intervention strategy, bDMARDs.  
 
The time to discontinuation of treatment and the assumed change in HAQ score 
post-discontinuation 
The time to discontinuation of bDMARD treatment was estimated using the BSRBR. 
Separate analyses were undertaken for those with a good and moderate EULAR 
response with the gamma distribution providing the best fit from the parametric 
models considered (Weibull, exponential, log-logistic, log-normal, gamma and 
Weibull frailty models). The individual patient characteristics were used as 
covariates. 
The median time to discontinuation was 1523 days for moderate responders and 
3363 days for good responders. It was assumed that the distribution of time to 
discontinuation was equal for all bDMARDs and also that this was applicable for 
cDMARDs. Patients were not assumed to discontinue NBT. Further details are 
provided in Stevenson et al. (7) 
For all analyses it was assumed that any reduction in HAQ score provided by the 
initial response would be lost (commonly referred to as a µrebound effect¶) once 
treatment was stopped. 
 
The costs associated with treatment 
The costs of each bDMARD and of MTX were taken from the British National 
Formulary.(33) The cost of MTX was assumed to approximate that of NBT. Both 
public (CTZ and GOL) and confidential (ABT and TCZ) Patient Access Schemes 
(PAS) were taken into consideration. In these PAS the first 12 weeks of CTZ 
treatment are provided free of charge, 100mg of GOL is provided at the same cost 
as 50mg, whilst ABT and TCZ are provided at a discount from the list price. 
Monitoring and administration costs were also included as detailed in Stevenson et 
al.(7)  
 
Hospitalisation costs and patient utility 
The hospitalisation cost data used in the model, conditional on HAQ score are 
shown in Table 1. These data were taken from the Abbvie company submission (34) 
and were derived from the Norfolk Arthritis Register database for Roche.(35) For 
FDOFXODWLQJDSDWLHQW¶Vutility the mixture model proposed by Hernandez Alava et al 
was used (36,37) which required the pain score for each individual to be simulated 
from the HAQ score. This method uses a much larger sample size including patients 
that span the entire range of disease; other published papers employ methods that 
have been shown to lead to biased utility estimates.  
 
 
 
Indirect costs 
In line with the NICE reference case (9) indirect costs such as lost productivity due to 
not working, were not included in our analysis. 
 
Assumptions regarding mortality 
It was assumed that bDMARD treatment would not influence the rate of mortality. 
This assumption was based on Michaud et al. (38) which concluded that changes in 
HAQ score did not contribute substantially to predictive values of mortality over and 
above the baseline values. The model assumes an increased hazard for mortality, 
compared with age and gender mortality rates (39), associated with baseline HAQ 
score category. These hazard ratios are provided in Table 1. 
 
Adverse events associated with bDMARDs 
A simplistic approach to estimating the impact of adverse events (AEs) associated 
with bDMARDs was taken. A review of AEs associated with bDMARDs estimated a 
serious infection was observed in 35 per 1000 patients (95% confidence interval 27 
to 46) compared with 26 per 1000 patients (no confidence intervals presented) in 
patients receiving placebo.(40) As such it was assumed that 9 people per 1000 
would have a serious infection which was associated with a cost of £1479 per 
episode and a QALY loss of 0.012 as GHWDLOHGLQ3IL]HU¶VVXEPLVVLRQWR1,&((41) 
 Ethical Approval 
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Results 
 
Due to there being only small differences in the discounted costs and discounted 
QALYs between many of the bDMARD sequences the incremental cost 
effectiveness ratio can be misleadingly volatile: accordingly, we present the average 
(median and mean) cost-effectiveness of the seven bDMARD sequences compared 
with NBT. Unfortunately, the absolute discounted costs and QALYs cannot be 
presented because of the risk of back calculation of commercial-in-confidence 
discounts. However, incremental QALY gains were between 1.5 and 2.0 and 
incremental costs were between £60,000 to £100,000. The ranges in the mean 
ICERs of the individual bDMARD strategies were relatively small, spanning £39,100 
to £42,200 for patients with severe RA and from £48,800 to £52,300 for patients with 
moderate-to-severe RA. The deterministic base case ICERs (the median of the 
seven mean ICERs produced by the bDMARD strategies) for patients with severe 
RA is estimated to be £41,600 per QALY gained: for patients with moderate-to-
severe RA the value is estimated to be £51,100.  The mean ICERs (assuming equal 
use of all potential first line bDMARDs and weighting the individual cost and QALY 
gains for the seven strategies equaly) were marginally lower, being £41,100 for 
patients with severe RA and £50,300 for patients with moderate-to-severe RA. 
Probabilistic results were similar to the deterministic results: the median (mean) 
ICERs for patients with severe RA were £41,300 (£40,700) and were £52,000 
(£51,100) for patients with moderate-to-severe RA. As such, all sensitivity analyses 
were run deterministically to reduce computational time required. The absolute costs 
and QALYs gained for the TCZ first strategy differed from the remaining strategies 
as TCZ cannot be used after RTX, if TCZ was used as the first bDMARD. 
 
Additional deterministic results are presented alongside the base case results in 
Table 2. Assuming that only those patients with fastest HAQ progression would be 
treated with bDMARDs the cost per QALY was reduced to below £30,000. This value 
is particularly important as it is a reported upper limit for cost-effectiveness by NICE 
IRUWUHDWPHQWVWKDWDUHQRWFODVVHGDVµHQGRIOLIH¶WUHDWPHQWV(6)  
 
Discussion 
The results from our primary analysis indicate that the ICER of a bDMARD strategy 
is in excess of £40,000 per QALY for those patients with severe RA and in excess of 
£50,000 for those patients with moderate-to-severe RA. Data presented elsewhere 
show that the values for monotherapy and for using bDMARDs before conventional 
DMARDs are greater than for our base case analyses.(7) All these values are 
greater than the threshold typically used by NICE for determining whether treatments 
should be recommended. However, there may be a number of factors that could 
reduce the ICER. These include: the emergence of biosimilars ± two biosimilars for 
IFX and one for etanercept have already entered the UK market at prices below that 
of the branded equivalent; the fact that intensive treatment with conventional 
DMARDs may prevent those with the least severe prognosis, in terms of HAQ 
increase, being provided with bDMARDs as argued by clinical experts in the 
appraisal process; the possible reduction in reducing the dose of bDMARDs for 
those in low disease activity or remission as summarised by Kuijper et al.(42) and 
Simpson et al.(43); and any potential mortality benefit associated with bDMARD 
treatment. Factors that could increase the ICER include: the possibility that second- 
and third-line bDMARD treatments are less efficacious than if they were used as a 
first-line bDMARD; that there may be HAQ increases while on bDMARDs; and 
should people with no EULAR response remain on treatment ± analysis of BSRBR 
data show that a quarter of non-UHVSRQGHUVKDG WUHDWPHQW LQH[FHVVRI IRXU\HDUV¶
duration.7 Exploratory analyses indicate that if the price of bDMARDs (excluding 
RTX) were reduced by 50% the mean ICERs would reduce to £24,500 for patients 
with severe RA and £31,500 for patients with moderate-to-severe RA. Assuming that 
the efficacy of RTX and TCZ following a previous bDMARD were reduced by 
reallocating 10% of the patients with a Good EULAR response to having No EULAR 
response increased the mean ICERs to £41,600 and £52,100 for patients with 
severe RA and moderate-to-severe RA respectively. Assuming that those with No 
EULAR response did not cease bDMARD treatment at 6 months but incurred an 
DGGLWLRQDO  PRQWKV¶ WUHDWPHQW FRVW LQFUHDVHG WKH PHDQ ,&(5V WR  DQG
£51,400 for patients with severe RA and moderate-to-severe RA respectively. 
 
Limitations with this research include that it only includes studies with EULAR 
endpoints and that the literature search was completed in 2013, however, neither are 
expected to change the conclusions. Analyses contained in Stevenson et al.(7) 
showed that the results when all studies providing ACR data were synthesised and 
then mapped onto EULAR responses using data from the Veterans Affairs 
Rheumatoid Arthritis registry were similar to those produced by EULAR data alone. 
A literature search of relevant clinical papers published since our review identified 
only two papers with data for the moderate-to-severe and the severe 
populations(44,45) and it is unlikely that these will change the broad conclusion 
regarding the cost-effectiveness of bDMARDs as a group at their current market 
prices. MTX was costed as oral tablets, rather than as an injection, which 
underestimates the cost of this treatment. This is unlikely to markedly affect the 
ICER as the use of MTX would be similar in both arms. The adopted method for 
generating utility estimates does not distinguish between reversible and irreversible 
damage within the HAQ score. 
 
Despite the different modelling approach used within this research it is noted that the 
conclusions are similar to those of Joensuu et al.(46) which concluded that tumour 
necrosis factor inhibitors do not seem to be cost-HIIHFWLYHDWDWKUHVKROGRI¼
per QALY. 
 
The supplementary analyses undertaken indicated that there may be subsets of 
patients in whom the use of bDMARDs may be cost-effective. Currently there are no 
agreed algorithms for identifying those patients who will have the worst prognoses 
on NBT. Research regarding prognostic factors in patients with RA could help 
identify those patients who could be treated cost-effectively with bDMARDs. 
 
Conclusion 
The estimate of the ICER for a bDMARD strategy in patients with severe and 
moderate-to-severe RA suggests that the use of bDMARDs has a greater cost per 
QALY than published NICE thresholds. However, the bDMARD strategies assessed 
in this research IDOOZLWKLQ1,&(¶VWKUHVKROGVLILWLVDVVXPHGWKDWRQO\WKRVHSDWLHQWV
with the worst prognoses on NBT are treated with bDMARDs.  
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